Iron is an essential element in maintaining normal structure and functions of the central
nervous system. Dangerous effects of decreases in the bioavailability of iron in the brain are …

Parkinson’s disease affects 5 million people worldwide, but the molecular mechanisms
underlying its pathogenesis are still unclear. Here, we report a genome-wide meta-analysis of …

… The first was the elucidation of the novel pharmacological properties of selegiline as a
selective MAO-B inhibitor by Knoll and Magyar and the original idea of Riederer and Youdim, …

Carbamate derivatives of N-propargylaminoindans (Series I) and N-propargylphenethylamines
(Series II) were synthesized via multistep procedures from the corresponding hydroxy …

The traditional role of iron chelation therapy has been to reduce body iron burden via chelation
of excess metal from organs and fluids and its excretion via biliary-fecal and/or urinary …

The presence of 5-Hydroxydopamine (5-OHDA) and 6-Hydroxydopamine (6-OHDA) in the
urine of parkinsonian patients on levodopa medication was reported by Andrew et al.(1993). …

The discovery that MAO can be differentiated biochemically and pharmacologically into two
forms, types A and B, with different substrate specificities and inhibitor sensitivities has …

It has been demonstrated that nutritional iron-deficiency induced in rats results in the
reduction of DA D2 receptor binding sites, leading to down-regulation of dopaminergic activity …

In Parkinson's disease (PD) an elevation of iron with staging of the disease has been observed
in the substantia nigra (SN), especially the zona compacta (ZC). The iron is found to be …

In several neurodegenerative diseases, iron accumulates at sites of brain pathology. Since
post-mortem examination cannot distinguish whether iron accumulation caused the damage …